Exact Sciences (EXAS) Competitors $52.82 -1.05 (-1.94%) Closing price 07/3/2025 03:12 PM EasternExtended Trading$52.82 0.00 (0.00%) As of 07/3/2025 04:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock EXAS vs. BIIB, INCY, UTHR, NBIX, EXEL, BMRN, RGEN, MDGL, HALO, and IONSShould you be buying Exact Sciences stock or one of its competitors? The main competitors of Exact Sciences include Biogen (BIIB), Incyte (INCY), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Exelixis (EXEL), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Madrigal Pharmaceuticals (MDGL), Halozyme Therapeutics (HALO), and Ionis Pharmaceuticals (IONS). These companies are all part of the "biotechnology" industry. Exact Sciences vs. Its Competitors Biogen Incyte United Therapeutics Neurocrine Biosciences Exelixis BioMarin Pharmaceutical Repligen Madrigal Pharmaceuticals Halozyme Therapeutics Ionis Pharmaceuticals Biogen (NASDAQ:BIIB) and Exact Sciences (NASDAQ:EXAS) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, institutional ownership, profitability, media sentiment, dividends and earnings. Which has stronger earnings & valuation, BIIB or EXAS? Biogen has higher revenue and earnings than Exact Sciences. Exact Sciences is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiogen$9.68B2.01$1.63B$10.1313.09Exact Sciences$2.76B3.61-$1.03B-$5.51-9.59 Do analysts prefer BIIB or EXAS? Biogen currently has a consensus target price of $188.48, indicating a potential upside of 42.12%. Exact Sciences has a consensus target price of $70.40, indicating a potential upside of 33.30%. Given Biogen's higher probable upside, equities research analysts clearly believe Biogen is more favorable than Exact Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biogen 0 Sell rating(s) 20 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.38Exact Sciences 0 Sell rating(s) 2 Hold rating(s) 19 Buy rating(s) 1 Strong Buy rating(s) 2.95 Is BIIB or EXAS more profitable? Biogen has a net margin of 15.07% compared to Exact Sciences' net margin of -36.06%. Biogen's return on equity of 14.03% beat Exact Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Biogen15.07% 14.03% 8.32% Exact Sciences -36.06%-3.75%-1.68% Do insiders and institutionals believe in BIIB or EXAS? 87.9% of Biogen shares are owned by institutional investors. Comparatively, 88.8% of Exact Sciences shares are owned by institutional investors. 0.2% of Biogen shares are owned by insiders. Comparatively, 1.2% of Exact Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has more risk & volatility, BIIB or EXAS? Biogen has a beta of 0.14, meaning that its stock price is 86% less volatile than the S&P 500. Comparatively, Exact Sciences has a beta of 0.95, meaning that its stock price is 5% less volatile than the S&P 500. Does the media refer more to BIIB or EXAS? In the previous week, Exact Sciences had 1 more articles in the media than Biogen. MarketBeat recorded 15 mentions for Exact Sciences and 14 mentions for Biogen. Exact Sciences' average media sentiment score of 1.16 beat Biogen's score of 0.83 indicating that Exact Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 7 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Exact Sciences 8 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryExact Sciences beats Biogen on 9 of the 17 factors compared between the two stocks. Get Exact Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for EXAS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EXAS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EXAS vs. The Competition Export to ExcelMetricExact SciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.07B$2.92B$5.55B$9.05BDividend YieldN/A2.44%5.24%4.01%P/E Ratio-9.597.9419.5920.21Price / Sales3.61281.76418.25119.02Price / Cash9.4842.7336.8958.10Price / Book4.077.518.035.67Net Income-$1.03B-$55.14M$3.18B$249.21M7 Day Performance-1.56%4.61%2.93%3.28%1 Month Performance-2.88%4.72%3.75%5.55%1 Year Performance18.50%5.92%35.20%21.09% Exact Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EXASExact Sciences4.9419 of 5 stars$52.82-1.9%$70.40+33.3%+22.3%$10.07B$2.76B-9.597,000Analyst RevisionBIIBBiogen4.9313 of 5 stars$125.59-0.4%$188.48+50.1%-41.0%$18.40B$9.68B12.407,605INCYIncyte4.4344 of 5 stars$68.10-0.4%$74.53+9.4%+18.7%$13.18B$4.24B212.822,617UTHRUnited Therapeutics4.9947 of 5 stars$287.35+1.1%$386.15+34.4%-5.3%$12.96B$2.88B11.471,305Positive NewsNBIXNeurocrine Biosciences4.9236 of 5 stars$125.69+0.2%$162.00+28.9%-7.4%$12.44B$2.36B42.611,800Positive NewsEXELExelixis4.7433 of 5 stars$44.08+0.9%$43.56-1.2%+109.1%$12.02B$2.17B20.041,147Trending NewsAnalyst RevisionBMRNBioMarin Pharmaceutical4.9465 of 5 stars$54.97-0.4%$93.45+70.0%-29.3%$10.54B$2.85B20.443,040Analyst ForecastRGENRepligen4.8159 of 5 stars$124.38+0.7%$172.83+39.0%+5.5%$6.99B$634.44M-276.401,778MDGLMadrigal Pharmaceuticals4.0879 of 5 stars$302.64+0.6%$420.63+39.0%+9.9%$6.72B$317.38M-16.7790HALOHalozyme Therapeutics4.8234 of 5 stars$52.02-0.4%$61.90+19.0%+3.9%$6.41B$1.02B13.84390High Trading VolumeIONSIonis Pharmaceuticals4.6752 of 5 stars$39.51-0.7%$57.88+46.5%-5.7%$6.29B$705M-13.211,069News CoverageAnalyst Upgrade Related Companies and Tools Related Companies Biogen Alternatives Incyte Alternatives United Therapeutics Alternatives Neurocrine Biosciences Alternatives Exelixis Alternatives BioMarin Pharmaceutical Alternatives Repligen Alternatives Madrigal Pharmaceuticals Alternatives Halozyme Therapeutics Alternatives Ionis Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EXAS) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exact Sciences Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Exact Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
